Elucidate Bio: Advancing Spatial Multi-Omics in Oncology
Oncology drug development continues to face low approval rates and limited ability to predict which patients will benefit from specific therapies. A central constraint is insufficient insight into the tumor microenvironment at true cellular resolution, leading to suboptimal biomarker selection, inefficient clinical trials, and high development costs.
At ZAKA VC, we have invested in Elucidate Bio, a Boston-based company developing spatial multi-omics services that integrate DNA, RNA, and protein data from the same tissue slide and apply advanced analytics to uncover biological patterns correlated with therapeutic response.
The Structural Challenge in Oncology R&D
Despite scientific progress, oncology remains one of the most capital-intensive and failure-prone areas of biotech research. Only a small fraction of drug candidates entering clinical development reach regulatory approval. One contributing factor is incomplete biological visibility — particularly within the tumor microenvironment.
Biomarker strategies often rely on partial signals. Molecular layers are frequently measured separately, without preserving spatial architecture. As a result, key cellular interactions inside tissues remain insufficiently characterized, complicating patient stratification and limiting predictive accuracy in translational research.
Elucidate Bio’s Approach
The platform integrates tissue imaging, molecular profiling, and AI-driven computational analytics to produce unified datasets that preserve spatial context. In addition to generating spatially resolved multi-omic data, Elucidate applies machine learning models to identify patterns within tissues that correlate with therapeutic response, resistance mechanisms, and biomarker relevance.
This enables research teams to:
- Characterize individual cells within intact tissue environments
- Identify biomarkers reflecting both intrinsic cellular states and microenvironment interactions
- Detect tissue-level patterns associated with therapeutic response
Elucidate’s service offering includes high-plex spatial transcriptomic profiling (covering thousands of genes), multiplex protein analysis, and genomic characterization — all derived from the same tissue section. By unifying these molecular layers within intact tissue architecture, the platform enables cross-modal analysis that would not be possible when modalities are generated separately.
The Team Behind the Platform
Elucidate Bio was founded and is led by Will Singleterry, Ph.D., whose background spans immunology, biotechnology, and life sciences leadership. His experience building and scaling multidisciplinary teams informs the company’s focus on translating complex biology into operationally usable outputs for research partners.
He works closely with a team that combines spatial biology, computational analytics, and translational science. Sizun Jiang, Ph.D., contributes deep expertise in spatial technology development and computational methods, grounding the platform in rigorous biological and analytical foundations. Gulpreet Kaur, Ph.D., brings experience across high-parameter imaging and commercial strategy, connecting advanced spatial approaches with real-world research applications. Jason Weirather adds strength in computational modeling and high-dimensional data analysis, supporting the integration and interpretation of complex multi-omic datasets.
Together, these capabilities expand how tumor biology can be characterized and integrated into drug development workflows. Rather than evaluating isolated biomarkers, researchers can analyze multi-layer molecular interactions within spatially organized tissue — improving hypothesis generation, translational alignment, and the identification of patient subgroups more likely to respond to therapy.
Our Perspective
We invest in enabling infrastructure that improves how drug discovery is conducted globally. Elucidate’s integration of DNA, RNA, and protein profiling from the same tissue slide addresses fragmentation common in single-modality workflows. Its applicability across multiple research programs creates leverage beyond a single therapeutic asset.
By adding spatial multi-omics capability to our biotech portfolio, we are reinforcing our focus on technologies that increase biological clarity in oncology research and support more informed development decisions.